You just read:

Comprehensive Analyses from Pivotal Phase 3 QuANTUM-R Study Demonstrate Consistent Overall Survival Benefit of Daiichi Sankyo's FLT3 Inhibitor Quizartinib in Patients with Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

Dec 03, 2018, 10:00 ET